Cargando…

Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study

The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadokostaki, Eleni, Tentolouris, Anastasios, Anastasiou, Ioanna A., Psichogiou, Mina, Iliaki, Evangelia, Eleftheriadou, Ioanna, Hatzakis, Angelos, Tentolouris, Nikolaos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/ https://www.ncbi.nlm.nih.gov/pubmed/35335014 http://dx.doi.org/10.3390/vaccines10030382

Ejemplares similares

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
por: Tentolouris, Anastasios, et al.
Publicado: (2019)

Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns
por: Koliaki, Chrysi, et al.
Publicado: (2020)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
por: Hatzakis, Angelos, et al.
Publicado: (2022)

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Pulse wave velocity and cardiac autonomic function in type 2 diabetes mellitus
por: Chorepsima, Stamatina, et al.
Publicado: (2017)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
por: Psichogiou, Mina, et al.
Publicado: (2021)

Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity
por: Tsiompanidis, Elias, et al.
Publicado: (2018)

Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

COVID-19 and diabetes: What does the clinician need to know?
por: Papadokostaki, Eleni, et al.
Publicado: (2020)

Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy
por: Agathos, Evangelos, et al.
Publicado: (2018)

Editorial: Understanding Diabetic Foot Disease: Current Status and Emerging Treatment Approaches
por: Tentolouris, Nikolaos, et al.
Publicado: (2021)

Dryness of Foot Skin Assessed by the Visual Indicator Test and Risk of Diabetic Foot Ulceration: A Prospective Observational Study
por: Panagoulias, Georgios S., et al.
Publicado: (2020)

Low-Glycemic-Index/Load Desserts Decrease Glycemic and Insulinemic Response in Patients with Type 2 Diabetes Mellitus
por: Argiana, Vasiliki, et al.
Publicado: (2020)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
por: Psichogiou, Mina, et al.
Publicado: (2021)

The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
por: Tzeravini, Evangelia, et al.
Publicado: (2022)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
por: Valentini, Diletta, et al.
Publicado: (2022)

Cardiac Autonomic Neuropathy Predicts All-Cause and Cardiovascular Mortality in Patients With End-Stage Renal Failure: A 5-Year Prospective Study
por: Doulgerakis, Dimitrios, et al.
Publicado: (2017)

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
por: Lagousi, Theano, et al.
Publicado: (2022)

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
por: Syrigos, Nikolaos, et al.
Publicado: (2022)

Complementary actions of finerenone and SGLT2‐i on renal outcomes?: An urgent need for more information
por: Rebelos, Eleni, et al.
Publicado: (2022)

Lipidomics Analysis of Free Fatty Acids in Human Plasma of Healthy and Diabetic Subjects by Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS)
por: Kokotou, Maroula G., et al.
Publicado: (2022)

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients
por: Havlin, Jan, et al.
Publicado: (2021)

Current data on the cardiovascular effects of COVID-19
por: Vlachakis, Panayotis K., et al.
Publicado: (2020)

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
por: Tychala, Areti, et al.
Publicado: (2021)

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Moisture Status of the Skin of the Feet Assessed by the Visual Test Neuropad Correlates With Foot Ulceration in Diabetes
por: Tentolouris, Nicholas, et al.
Publicado: (2010)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

The application of machine learning to imaging in hematological oncology: A scoping review
por: Kotsyfakis, Stylianos, et al.
Publicado: (2022)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Agrati, Chiara, et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4dbkhfv3oph1us382pat5envti